<SEC-DOCUMENT>0001129928-12-000054.txt : 20120816
<SEC-HEADER>0001129928-12-000054.hdr.sgml : 20120816
<ACCEPTANCE-DATETIME>20120816140709
ACCESSION NUMBER:		0001129928-12-000054
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120816
FILED AS OF DATE:		20120816
DATE AS OF CHANGE:		20120816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		121039583

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;August 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release Dated August 16, 2012: Oncolytics Biotech&#174; Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN&#174; in Combination with Cyclophosphamide in Patients with Advanced Malignances</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;August 16, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;&#160;Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="onclogo.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in Combination with Cyclophosphamide in Patients with Advanced Malignances</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- August 16, 2012</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies (REO 012).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are pleased to complete enrollment of this technical study examining cyclophosphamide&#8217;s potential to modulate the immune system&#8217;s response to REOLYSIN,&#8221; said Dr. Matt Coffey, COO of Oncolytics. &#8220;Studies of this type help to advance our understanding of the interaction between the immune system and our product.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The primary objective of the open label, dose-escalating, non-randomized, 36-patient study is to determine the Minimum Effective Immunomodulatory Dose (MED) of cyclophosphamide necessary to obtain successful immune modulation. Secondary objectives of the trial include assessing the safety profile of the combination and gathering any evidence of antitumor activity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Eligible patients include those who have been diagnosed with advanced or metastatic solid tumors, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no standard curative therapy exists.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The principal investigators for the study are Dr. James Spicer of King&#8217;s College, London, Dr. Johann de Bono and Dr. Kevin Harrington of the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#8217;s expectations related to the U.K. Phase I clinical trial with REOLYSIN in combination with cyclophosphamide , and the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta, T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">IRG, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tom Caden</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20th Floor, 1251 Avenue of the Americas</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10020</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">tcaden@investorrelationsgroup.com</font></font></div>
</td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``@$!`@$!`@("`@("`@(#
M!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,#`P'"0X/#0P.
M"PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/W\
MHHHH`****`"BL/XB?$G0_A/X6NM<\2:KI^BZ/9+OGN[R=88HQ]6/4]`!R3P*
M^!/VE_\`@X"\+^%+FXTWX9>')O%%Q'E!JFI,UK99_O)$/WLB_7R\]LUP8S,L
M/A5>M*WEU+A!R=D?HO17X?:K_P`%._VIOVE=5EM_#.H:RBR'_CQ\*Z(&*9[!
MU1Y0.G5\TZ+P!^V]KZBY$GQY42<X.JWMO_XZ9%Q^5>1_K-"6M*C.2]#3V#ZL
M_;^BOPYNOB'^VG\"5-W>W'QHMH(?F::_M[G48%'N95D3'UKN/@O_`,%\?BGX
M#OH[3QQHFB^,+.,[9F$7]G7P['YD!CXYX,8/OWHI\3X?FY:T)0]4'U=O9G['
M45\Y_LF?\%0?A7^UT\.GZ/JCZ)XEE'_(%U7;!<R''(B;)24=?N$MCD@5]&5[
M]#$TZT%.E*Z,91:=F%%%%;B"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"O$_VVOVY/"?[$?PT&M:^_P!MU6^#
M1Z3I$#@7&HR@?^.QKD%G(P!P,L0I[;]H?X\Z'^S1\(-;\:>(YO*TO1;<RLJD
M>9<2'B.%`>KNQ"CW//&37XJ^$/#/Q$_X*_?MEW%Q=W$D$=PWFW=Q@O:^'M.5
MOEC0>N#M5>"[DL>K,/"SC-)4.6C05ZDMEV\V;4J:E=RV0[6/$'QR_P""OWQR
M^S6Z37UO;2;TM8W:#1O#\).`S'D`XS\QW2/@@9X`_0/]DW_@B#\,O@G8VNH>
M-4'Q!\1H`S_:U*:;"_HD&?G'O*6!Z[17T[^SA^S;X4_99^&%EX3\(:?'9:?:
MJ#+*0#/>RX^::5OXG;UZ`8````'?5E@,@IP_?8KWZCU=]E\ASKMZ0T1G^&?"
MNF^#=)CL-)T^QTRQA&([>T@6&)!Z!5``K0HHKZ",4E9&`5Y7\>?V*?AA^TOI
M\L/C#PAH^IW$@(%\D(@O8O=9TPX]<$D'N#7JE%34I0J+EFDUYC3:V/QY_;8_
MX(D>*_@1%/XJ^%EYJ'BS0[,^>]@1C5K``[MZ;,"8+@'*@.,?=.,UUG_!-?\`
MX+,WWAG4['P%\8[Z2[T^1UM;#Q'<']_9-G`CNR>63/'FGYE_BR,LOZM5^<W_
M``5W_P""6-IX[T/4OBE\.M.6#Q):(]WKNE6T>%U6,#+7$:CI,O5@!^\&3C?]
M[Y?&974P4OK6`?K'HT=$*JG[DS]%+*\CO[9)HG22*50Z.C;E=3R"#W!'.:EK
M\Q?^"(O_``4,GU&:#X,>,;UIYDC)\,7D[Y9E526LF8]<*"T>>P9>R"OTZKWL
MNQ\,715:'S79]C&<'%V84445W$!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`445#J.H1:7937$[K'#`C2.QX"JHR3^5#8'Y)
M_P#!>W]J>?QM\6])^%&EW#MIOA=4O]42,G$][*N8T('79"P(]YCW6ON+_@F%
M^QS;_L@_LS:;8W5NB>*_$*)J>NS%1O$K+E(,_P!V)3MQTW;S_%7Y?_L8:+-^
MW)_P5/LM:U6,W-GJ&OW7BB]63+*L,+/-'&?]G<(8\>AQ7[H5\IDE-8K$5<PG
MWM'R2.BJ^6*@@HHHKZLYPHHHH`****`"D90X((!!]:6B@#\1_P#@JW^S#=?L
M2_M>Z?XO\(>9I.C^)+C^W-(EMUV+I][%('EB3'0*^V11T"R;<84U^MG[(G[0
M%I^U!^SOX6\<6HCC?6K-6NH4.1;W*$I/']%D5P,]1@]Z\2_X+6_!*'XM_L-:
MWJ*0B34?!5Q%K5LP'S!%/ES#/IY4CL?=%]*\7_X-X/B_)JOPR\>^![B8L-$O
MH-6M%)Z)<(T<BCT`:!3]9*^3PL?J>:2PZ^"HKI>?]7.B7OTU)[H_2&BBLSQ3
MXQTCP59QW.LZIIVDVTC^6LMY<I`C-C.T%R`3P>/:OJY225V<YIT5C^%OB%H7
MCD3_`-BZUI&K?9L>;]CO([CR\YQNV$XS@]:V*4)J2NG<`HK)\6>.=%\#P0RZ
MUJVF:1%.Q6-[VZ2W5R!D@%R,G'/%6?#WB.P\5Z7'?:9>V>H64V?+GM9EFB?!
M(.&4D'!!'![4*2O8"[1115`%%9?BOQKH_@FQ^U:SJNG:5;#_`):WERD"?FQ`
MKA_^&QOA-]K\G_A9/@42YQM_MRVSGT^_64ZU.+M*27S&DSTRBLKPIXWT;QM:
M&XT;5=-U6`?\M+.Z2=?S0D5JU<9)JZ$%%&:R/%GCO1?`UD+G6M6TS2;<_P#+
M2\NDMT_-B!1*22NP->BO,E_;)^$KW'E#XE>!3(3C']N6W7T^_7<>%O&VC>-K
M#[5HVJ:;JML?^6MG<I.GYJ2*B%>G)VC)/YCL^IJT49HK4045B>)_B/X?\$2P
MQZUKFC:/)<`M$M[>QVYD`ZE0Y&<9[>M:6CZQ:Z_IT-Y97%O>6EPH>*>"021R
MJ>A5AP1[BHC-/2^H%FBBBK`**Y/5OCQX*\/:I/8ZCXN\,:?>VK;);>XU2"*6
M)L9PRLP(.".OK736&H0ZG:1W%O+%/!,H>.2-PR.I&001P01W%1&I&6B8$U%%
M9'BKQ]H?@>.!]:UC2M)2Y)$37MW';B0@9(!<C.!Z4YS45=@:]%9GA7QCI/C6
MQ>ZT;4].U6VC?RVEL[E)T5L9VDJ2`<$''O57Q+\3O#G@NZCM]9U_1=(GF3S(
MX[R^BMW=<D;@'8$C((R*3J12NWH!NT5R/_"__`O_`$.GA+_P<6__`,71_P`+
M_P#`O_0Z>$O_``<6_P#\74^WI_S(=CKJ*Y'_`(7_`.!/^AT\)_\`@WM__BZZ
MFRO8]0MHYX9(Y895#HZ,&5U(R""."".]5"I&7PNX6):*IZ_XAL?"NDS7^I7E
MII]C;+NEN+F58HHAD#+,Q``R0.3WJCX/^(_A_P"("W!T+7='UH6FT3&QO([C
MRMV<;MA.,X.,]<4.:346]1&U1115@%%4M>\2:?X7L&NM2OK+3[9!EI;F=88U
M^K,0*X&?]L3X3VUV8)/B3X&253@J=<ML@^GWZSG6A'XFE\QI/H>ET5A^#_B7
MX>^($!ET/7='UF,`$M8WD=P!_P!\$UN54)J2O%W$%%&:X7QK^TU\._AI>-;^
M(/''A/1KA<[HKO58(I!_P$MG]*FI5C#63L.QW5%>5:7^W%\'M:G$5K\3O`TL
MA.`!K,`)/IRU>B^'?%>F>+K%;K2M1L=2MF&1+:W"3(?Q4D4J=>G/X))_,'%K
M<T****U$%><_M=:U+X<_94^)>HP$K-8>%-4N$(."&2SE8?J*]&KSS]K/09O%
M/[+?Q(TN!6:?4O"VIVL8`R2SVDJ@?F:PQ-_92Y=[/\BH?$C\P/\`@WFT"*^_
M:C\8ZBX!EL?#+11GNOF7,&2/^^,?C7[!5^//_!O5XEBT_P#:I\6Z:[!9-1\,
MO)'G^(Q7,&1]<.3^!K]AJ\3A=KZBK=W^9KB/C"BBBOHC`****`"BBB@`HHHH
M`X+]J+PY'XO_`&;/'^E2KOCU#PYJ%N1C)^:VD&1[Y/%?EC_P;W:X]I^UMXIT
MX',5_P"%99&&<9:.ZML'\G/YU^I/[5WB>+P7^S#\0]6F8*FG^&]0GZXR5MI,
M#ZDX`]R*_+G_`(-[/#[WG[5WBS4\$0Z?X7DA9L9`:6ZM\#\D;\J^7S7_`)&>
M&Y=[O_@'12_AR/V(K\^/^#B$D?LT^",`9/B?_P!M9J_0>OSW_P"#B/\`Y-I\
M#]O^*G_]M9J]#/W_`+!4]/U1G1^-'Y^_`3Q-\3?V*+#PE\:?"Y9=!UV>>Q=O
MF>TN3%(1)9W*CIN50ZGWR#E3C]JOV,OVS_"?[:WPKB\0^'9EM[VW"QZII<K@
MW&F38Y1AW4X)5P,,/0@@?,?_``1V^%/A_P#:#_X)GZIX1\5:?#JNB7VNWUO/
M"XP1E875U/575B&5A@@@&OD/XX_`KXG?\$<_VD[+Q7X5O+F\\,7<Q2PU!T)M
MM1@)):RNU'`?`]LX#I@C"_/8&=;+Z,,1'WJ,DG)=4^YO42FVGNCZ7_X.,K=G
M^%WPRE"@JFJWB$]QF&,C_P!!_2O</^")AS_P3K\''C_C\U'_`-+9J^1O^"J_
M[67AK]MO]A_X=>,_#KF&YL/$1M-5TYW#3:9</:2-Y;^JGRR5?HP'8@@?7/\`
MP1,_Y1U^#L=[S4O_`$MFKLP=6-3.9U(.Z<$U^!$XM4K/N?6-?GQ_P5,_X*PW
M7P'\37WPW^']U%:>*+6V+:GJYA%P-/=D#);Q*3CS"""78$)D#!;.W]!Z_GS_
M`&T=&O/`'_!0GQY_PD\4KK'XOFOIA("3/:R7'G1L!W5H77`'&#BNOB3&U:&'
MBJ3MS.S?9$T(*4M3[@_9A_X(ZZG^T+HEEXZ_:`\7>*M7UC6(UNX])%XQD@C<
M;@LTK[F#$'E$"[>F<CCZ"G_X(M?L\3:7]F'@RZC;&//75[L2_7)DQ^E?3V@Z
MW:>(]&M=0L)X;JPO84GMYHF#1S1L,JRD<$$$$?6KF1ZBNRADV$A!)P4GU;U;
M^9,JDKZ.Q\N_LS_\$D_AE^RS\6V\8>'[SQ1=7D2E;2VO+\-;VI/!;"*I<XX`
M<L!Z9P1]149HKOP^&IT(\E*-EY$.3;NSX3_X*]_\%,=2_92M['P-X(>&+QGK
M-I]KN;]U$G]D6S,54JIX,KE6QNX4+G!)%>3_`+$7_!*)_P!K_P`!:?\`%+XV
M^*O%&MS^)%^V6.GB];S'MV/R22RMEAO'S*J;<*5YYP/!?^"Y7AC4M$_;YU>]
MO(Y!9ZSI5C<V#D':T:PB%@/I)&_'O[U^KW[`WC"Q\<_L7_#*_P!.>-[8>&[&
MU.P@A)(85AD7CNLD;@^X-?+8>/UW,JM/$ZQAM'IZLZ9KDIIQW9YQ)_P1@_9W
MDL!;_P#"$3J0,>:-7N_,^N?,_I7RC^W-_P`$N]2_8>\&W7Q4^"7BOQ1IEOH)
M6;4;'[81<6T18#S8Y$P7121N5P<+DY(!%?JKD=,C->3?MV:G9:3^QC\4IM0>
M);4^%M1C._H6:V=47W)<J![D5ZV.RK"NC)Q@HM)M-:-?<9TZLN97=SYL_P""
M1?\`P4WU/]JYKSP+XX\A_&6DVGVNVU"-1&-6@5@K;E'`E4L"=O#`YP,&ONRO
MPX_X(@:3>ZE_P4'\.S6JN8+#3=0GNR!D"(V[1C/MYCQCZD5^X]9<-XNIB,)S
M57=IVOWV'B(*,K(_)/\`X.*?^2W?#O\`[`<__I17WM_P3(_Y,'^%G_8#B_\`
M0FKX)_X.*?\`DMWP[_[`<_\`Z45]Z_\`!,@X_8'^%G('_$CB_P#0FKCR]_\`
M"Q7]/\AU'^Z1[O110#GIS7U5SG/C/_@I[_P2XTS]KO0I?%7A6*WTSXCV$7RO
MPD.MHHXAF/0.!PDG;@-E>5^2/^":W_!2S6_V//&9^%'Q82_MO#-M=-9QR7BL
M+GPU/N(*,#R8,]1_!RP^7(K]@Z^)/^"O'_!/+P_\>_A-KGQ&TQ8-(\:>$M-F
MOYKE4Q'JUM!&9&AE`ZN%4['ZC&TY!&/G<SRZ=.?UW!Z36ZZ27^9O3G=<LCWG
M]J[]MCP9^R5\'E\7:Y?07D5_'_Q*+.UE5Y=7D*Y58L<;,$$O]U00><@'\L_A
M5\*?B?\`\%H/VF;OQ+XDNKC3/".F2B.ZNHU/V72;?.5M+53PTI'))]=S=@?*
M_P!BWX(Z[^W]\?O"G@'6O$^HQZ+H5C(P>64RM8V,3;VA@4\*69P!V&<\A0*_
M=OX._!SPY\!/A[IWA;PKID&E:)I<?EPP1CDGN['JSL<DL>222:XL.ZN<24ZO
MNTH]+[OS\BI)4M%N0?`_X'^&_P!G;X<:=X4\)Z=#IFC:;&$CC4?/*W\4CMU=
MV/)8\DUYE^U/_P`$W_AE^V+XSL/$'C6SU:?4]-LQ80O:7[VZ^4)&D`(&03N=
MCGW^E>]T5]14PM*=/V4XIQ['.FT[H_.[]L#_`((Y?!;X-?LO>._%6A67B&'6
M/#^C3WUH\NJ-*BR1KN7*D8(XZ>E?)O\`P2%_8P\%?MG?$[Q=IGC:'4I[/1=,
MBNK=;2Z-N?,:7:22!DC';WK]6_\`@HG_`,F*_%;O_P`4U>?^BS7Y^?\`!NJ?
M^+V?$0<?\@2W_P#2BODL=@</',Z%*,$HN]U]YU4YR]F]3ZB7_@A5\`%/_(-\
M3X[C^V'Y_2OKSPYX>M?"FA66F6$2P6.GP);6\2](XT4*JCV``%7:*^KH8*A1
M;=**5^QS2FWNSYF_X+#?\HX/B1V_=6'_`*<;6ODS_@W%).O?%O@9$&E?^A7=
M?6?_``6&_P"4<'Q(S_SRL/\`TXVM?)?_``;B9_M[XM_]<-*_]"NZ^>QC_P"%
MNC_A_P`S>G_"9^IM?$G_``59_P""H<G['R6W@[P?%:7GCO4[;[5)/./,AT>!
MLA7*_P`4K$':IX`&XY!`/VW7X1?\%D_#.K>'_P#@H/XVGU1)A%JRV=Y8R/G;
M+;_9HHQMSV5HW7ZJ:[.(\;5PV%YJ.[=K]B:$%*5F?1O[)'_!,WQ=^WMX:LOB
M=\=/'/BF[T_6Q]ITW35N/](G@)RLK%@4AC8<JB+DJ0<C.*^I;;_@BS^SQ;Z9
M]F;P;=3-C'GR:O=F7ZY$@&?PKVG]E3Q/I?C']FKP'J.C2P2Z9<:!9>08L;4`
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M]58=F4@CL:^'OBQ_P;]^"]8UV34?`OC37O![,2R6LT0OHX3Z(^Y)`/\`>9C[
MU\YC,LKK%O%**JQ?V6[6]-TS6$UR\NQZ[XI_X(N_L]>)K`PQ>#[K29""!-9:
MK<K(OO\`.[*?Q!JE^S'_`,$?_!'[+/QLC\8:)XH\8W<=JA^SZ;/=B.$2'C=(
M8@OF@#HK#'<YP*^<=5_X)C?M4_`.Q:[^'GQBN=;CM1OCLEU:XM'D`[".8M$3
M[%@*YG]G/_@M=\3?A+\6X?!_QEL+?4[*VO\`^S=2G:T%KJ6F.'V,S!,)($;J
M-H)`.#TS,<3@Z56+Q.'=-WT?2_JA\DI)\LKGZV44V.02*&!!4C(([TZOK4SG
M"HKVSCU"VDAE57BE4HRD9#`C!'Y5+10P/PK_`&8=8D_8(_X*HVFF:G(;73]&
M\17'A^\>3Y5-K.7B25O]G:\4OT`K]U`01D$$&OR=_P""^O[*$WAWQWHWQ;TJ
MV8V.N(FE:TR+_JKF,?N9FQ_?C&S/8PK_`'J^O/\`@E!^VA!^UG^S790:A=(_
MC'PC''INL1LW[R<*N(;G'7$BKR?[ZO[5\GDU183$U<!/O>/IV.BJN:*FCZFH
MHS17UASA1110`4444`%%%,GG6VB:1V5$0%F9C@*`,DDT-@?'G_!<'XY0?"O]
MB74-$BG6/5/'-W%I4"!L-Y2L)IVQ_=V)L/O*!WKR_P#X-Y_@[)H7P=\;>.+F
M$HWB/48M-M&9>6BMD9F8>Q>8K]8O:OD[_@I-^TAJ'_!0G]L[3_#G@Q7U/1]+
MN%\/^'XHSE+Z9Y`)+@>@=\`'_GG&I/<5^PW[+WP*L/V:?@-X8\#Z<0\&@620
M22@8^T3'+S2X_P!N5G;VW8KY/!R^N9G+$KX*>B?G_5SHE[M/E>[/0:^*O^"W
M'[//C3]HKX!^$].\$^'[WQ%?:?KXN;B"VV[XHOL\J[\,1D;F`X]:^U:*^BQN
M%CB:,J,W9,QA+E=SY'_X(P_!'QA\`/V4-1T+QKH-[X>U23Q#<W<5M=%=[0M#
M;J'^4G@LC#GTKZ3^+OPB\/?'7X?ZCX7\4Z;!JNB:K$8YX)!^(93U5E."&'((
M!%=+FBE0PD*5"-#=)6U"4KML_$K]J3_@CG\6OA!\1M0TKP+H^J^-O!U^XN;6
MXM70.H7=L2X0L/WB;B`P&""2,$D#])?^"47PF\2?!#]B#POX;\5Z3<Z)K=G/
M?236<Y4R1"2[E=<[21RK`_C7TA17!@<CH86NZU)O72W1>A<JKE&S"OE[_@H#
M_P`$Q/"G[;VFP:B;IO#WC73X/)M=6BB#K,@R1%.G&]`2<$$,N>#CBOJ&BO2Q
M.&IUX.G55TS.,FG='Y?_``C^'_[9G_!/BT&@Z+H6G?$SP9:L?L]JEP+J.!<_
M\L@62>,=]N"H)Z5ZE8?\%)OVA;U3:K^RUXD.H`8+&YFCAS]6AZ?C7W=17G4L
MIG17+1K24>VCMZ73+=2^Z/D3X`?%;]K'Q_\`%NPO/&'PZ\%>%?`\GR7=I+?8
MO50D?O$96D+.H_A954\@XX(^NZ**]##4'2CRRFY>MO\`(F3OT/"_VY/V$/"?
M[;_P\@TK6S+IVLZ9ODTK5[=`9[)V&"I!^_&V!N0D9QD$$`U\8?!/X,_M:?\`
M!,^6]T;POX<TOXG^!KBX-PMK;S;U1CU=$+++$S`#(`=?J>:_4.BN3$Y52JU%
M7BW&?=?KW*C4:5NA\,+_`,%./CE'#Y4G[*_C,W@XRL\_E[OK]GZ?C7D_QY\$
M_M=_\%([.+PUJG@K3_ACX'DF66>&ZN1$)MK`J9B2TT@4\A515W`$CC(_3_-%
M9U,JG5CR5JTG%[K17];(%4L[I'SA_P`$_P#_`()R^&?V%O"5T;6Z;6_%FL(J
MZGJ\D>S>H.1#$O.R('G&26/)/``^CZ**]'#X:G0@J=)62(E)MW9^;'_!;S]D
MCXE?M'?%7P/J'@CPAJ?B.ST_2IK>YEM-A$+F;<%.6!Y!S47[/'Q[_:U_9X^"
MWAWP59?L^1ZC9^'+06<-Q/(ZRRJ"2"P67&<'''I7Z645YD\F7UB>)IU)1E+>
MUO+R\C15/=Y6CX(_X;D_;`_Z-NLO^_TG_P`=KZW_`&8_&?C+X@?!72-7\?\`
MAVV\)^*;T2O=Z5!(9%M`)76,$DGYB@5B,G!;':O0**Z\-A*E*7-.JY>3M_D1
M*2?2P5P7[4'AJ_\`&G[-OC_1=*MGO-3U?PYJ%E:0*0&FFDMI$1!GC)8@<^M=
M[D>HHKLJ04XN+ZDIZW/RB_X(\?L2_%;X"?M??\)!XQ\$:OX?T>/1+N`W5UL"
M&1FCVJ,,3DX/;M7ZNT45QY=E\,'2]C3;:O?4NI4<G=A1117>0>5?MO\`@S5?
MB-^R+\1-`T.QEU+6-7T&ZMK.VB(#SR-&0J#.!DGCDU\7?\$0_P!DGXD_LX?%
M/QSJ'C?PCJGARTU#2H(+:2ZV`3.)BQ5=K$Y`K])J*\ZOEM.KB88IMIQ+4VHN
M*"BBBO1(/`_^"G7PRU_XQ_L->.O#7A?3)]8US4XK3[-9PX$DVR]MY&`R0.$1
MC^%?-W_!#;]E;XA?LVZG\29_''A;4?#<>L1Z<EF;O8#<&,W)?:%)Z;UR?>OT
M-HKS:N60GBHXMMWBK>77_,M3:BXA7@G[=/[`7A']N/P1!9ZVTFF:]I:L=+UB
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MKJZ;&6DF$IC93G@+&V`.Y)KSW1O^"CW[4/A`K!XG_9KU+4Y$&&ETV&ZB#>_`
ME'Y&OT)HKDJ9=5<W.G6DK^C7RT*C.RLT?GUXD_X*#_M2?$K3FL?!O[.>IZ#?
M3?(EYJBRRK"3_$!(L2`CU8D>U>>_LP_\$7_&_P`1/C0/B'\=M3M@]U?G5;O2
MH)A<7.I3E]Y$TB?NT0MU5"V1Q\O;]1\T;AZBLWDT:LU/%3<[:I.R7W(:JM*T
M5815"#```I:**]DR"BBB@#E/C;\&M#_:!^%^M>$/$EL+O1M<MFMITX#H3@K(
MA[.C`,I[$`U^)6IZ?\1_^"/O[9:R1AIH[=B87=2EGXCTUFR5/7G`&1R8Y%SS
M@$_O!7E/[6_['_A#]LCX82^&_%5JQ:/,FGZA"`+K3)L<21MZ=,J>&'7L1XF;
MY6\0E5HOEJ1V?Z,UI5%%V>S)?V3OVN/"'[87PNM_$WA2]1QA4OK"1@+K39B.
M8I5[>S=&'(KU&OPG^*_P"^-W_!)3XRIK^E7M[;:>9/+M->L8V?3]3CSD13H<
MJ"0!F.3N,J3@-7VM^R=_P7F\$?$*RM=,^)UC)X,UL@(^HVZ/<:9<-TW8&9(L
MGL0P'=JYL#G\+^PQJY*B[[/YE3H6UAJC]`J*YOX<?%_PM\7=)%]X7\1Z)XAM
M"`WFZ?>QW"@'UVDX/L>:Z3(]17T,)J2O%W,`HILLR01L[LJ(HR2QP`/6O!?V
M@?\`@I=\&_V;["?^V_&6FZAJ4((73-(D%]=NP_A(0E4/_71E%16Q%.DN:I))
M>;'&+;LCWPD`$D@`5^7W_!7?_@JQ:WNEZG\*/AKJ,=P;@-;>(=:MI,H$SA[2
M!AU)^Z[@XQE1G)QXS^V/_P`%?/B)^V#>/X-\!:=?^%_#FJR?9EL[$M/JNK!C
M@([(,@-T\N/KR"S"O=/^":G_``1A?PWJ%AX\^,5E&][`5N--\-28D2!NHDNN
MH9@>1$.`?O9/RCY?%YE6Q\OJV`VZRZ6.B--0]Z9K?\$3_P#@G3/\.K"/XO>-
M+%K?6]2@*^';*:/$EE;R+\URP/2213A1V0D\[\#]':;%"L*A5```P.V*=7T.
M7X&GA**HT]E^+[F$YN3NPKYW_;^_;AN_V+M-\%M8^';/Q!<^,=4.F*+O4#90
MVIPIWNX1OERPR<<`$^U?1%?+7_!3?]C'Q/\`MA:7X`3PT_AQG\):PVHW5MK,
MDD=O>1X3]V=B/D$K@@CH34YDZRH2=#XM+?>APMS>]L4/C5^W]XT_9W\$SZ_X
MB\.?"G4+6UPSV>D^/]]],,@8BBEM4\QN?NJ<G!KZ%^`_Q9'QR^$FA>*UT;5O
M#XURU6Z%AJ40CN;<$G`8`G@XR#W4J<#.*^8/B=^QIXS^(W@O4-)MO@_^SGH%
MW>P-%#J2-/+-9,>/-C"6D;;UZJ0XP0#VP?;_`-B+]GO7OV8O@39^%/$?C'4/
M&VI6\SSF]N0P6W5L8@CW$MY:X.-Q)^8]!@#EPDL3[9J:?(UY:/\`!_@.25M#
MU^LGQWXG_P"$,\%ZOJXA^T_V7937?E;MOF>7&S[<]LXQG!K6K%^(_A^;Q;X"
MUO2;=D2?5+">TC9\[49XV4$X[9->K44N5\NYF>8_L&_M82_MF_L]V?CB?18]
M`DN;NXM6M$N3<!?*?;NW%5Z]<8KVBO`O^";7[,&O?LB?LPV/@OQ'=Z;>:I;7
MUS=/)8N[P[99,J`7522!UXKWVL,$ZGL(.M\5E?U*FU?W=@KYGF_X*`7OQ/\`
MCYXB^'/PH\(1^+M4\'L8]=U;4=2_L[2].E#E#&&6.221@ZLORIU1L9`)KZ8K
MY(T7]AKQ?^S9^TQXN^(OPDU/0+VQ\>2-/K7ASQ`98(A,9&E\R"YB5V7YW<A6
M0@!R.>,1C76O#V6U_>MO;R^81MU.M^+?[27Q@_9\\$7WBKQ%\-O"VO\`A_28
M3<ZA_P`(_P"(I6O;6%1EY1'/;HL@5<D@,#@=*]0_9P_:&\._M1_"72_&?A>>
M6;2=45@JRILF@D5BKQNN3AE88X)!X()!!/DOQW\)_'O]H+X6ZSX/CT?X=^"+
M3Q#:2:?>ZFNNW6JSQP2*5D\J(6L(W%20-S8&:]`_8V_9<TK]C[X":3X&TJ]N
M=22P+SW-Y.H1[J>1BSOM'"C/`7)P`.2>3C0G6=?2_);KW\NHVE8]4KEOBKJO
MB_2?#\,G@O2=!UG5&G"R0ZMJ4MC`L6ULL'CBE);.T;=H&"3GC!ZFBO2G'F5K
MV(/CX_MZ?%<?M9#X-?\`"M_!)\4G3?[5^T?\)1<?81#MW??^R;]W;&S\:^D_
MA+K'C75])NF\;Z-X=T2^2;%O'I&IRW\4D>W[S-)#$5;=D8`/'?M7BK?L@>(S
M_P`%-%^,XO-)/AH>'/[)^S>8XO/.V[<[=NW;CG.[/M7TQ7G8&G6O)U9/1NVV
MJZ="I-=`KF/C3\0_^%0_!_Q3XK^RF^_X1G1[O53;;]AN/(@>79NP<;MF,X.,
M]*Z>N._:!\!W?Q2^!/C3PQ8200WWB/0K[2[>28D1QR3V[Q*S8!.T,P)P"<5W
M5N;D;CO9V^X2W/G/]GO_`(*$^-_VCOA78^+-*\,_"S2;&_>5$MM7\=/;7:&-
MRA+(+-L`E21SR,'O7TG\(/$7B+Q1X36]\3:?X?TZ]FD+0+H^J/J-K+"0"KB5
MHHN2=W`4C&.3GCXZ_9C_`&`?'G[/WP?T_P`+ZG\,/@)XSO+*6:1]5U&XE-S<
M"21G`8M9,3M#;1ST45];?`6R\4:3X2:P\2^'_"7AP6)6'3[/P]=R3VJ0!0`,
M/#%L(.0%4$8`Z=*\W+IUVHJO>]M;[7_+\2II7]T[F@D*"20`**9/`MS$T;@,
MC@JP/0@]17KL@^9?!W_!0>^_:/\`B%KWA_X,>#8O%]GX9D$&I>(=4U,:;I4<
MC%@%B*QR2S9V,050#`ST()]*\$^*?B\_B^TMO$GA+P)#HD^?/O=-\0W,D]OQ
MP!#):KO)/'WA_CXI\#_V(/B!^P[XM\1M\(]4\*Z[X,\2W?VZ30/$GGVT]A*!
MM_<W42ON&W`^>,\`=\L?:_".N_&+5O$U@-=\-_#[1=%5S]L-KKEU?W3)M/\`
MJP;:)0<X^\3QFO'PDJ[5\0VI7V2]WY:&CY=D>IT445[!F<;^T+\5&^!WP.\7
M>,5LUU%O#&D76IBU,GEBX,,3.$W8.,D8S@UPO[)G[:WAW]I#X`>'_&6H7N@^
M&[W6$E,VFR:K$[VK)-)%@EMIY"!N5'##ZUUW[4/PTOOC1^SKXW\(Z9-;P:AX
MET2[TRWDN"1$DDL3(I8@$A<GG`/%>6?L9_L!>&?@I^S=X9\,>,O"?@?7O$NF
M13"^OAID5S]H=YY)`?,DC#MA'5<D?P^E>94EB/K*5/X.7KM>Y:2Y;LL>"?V^
M+3Q[^WCJOP;TW3+"\L--T0:J-;MM06997VQ,8MBKC@2XSNSD=*^B:^5/AG^P
M3>?"S_@HWK/Q6T>W\-:1X*O_``^--ATVPC,$T<^V$,WEJ@0`^63D-DY'%?5=
M;8%UG&7MUKS.WIT%*VE@HHHKM)"BBB@#@_VF/C"_[/OP#\5^-8]/75'\-:=+
M?"U:7RA.4&=N[!QGUP:J?LF?'9_VF/V=O"WCJ335TB3Q':FX:S6;SA`1(Z8W
MX&?NYZ#K1^US\)M0^.W[,_C7P=I4UM;ZEXCTJ:RMI+DLL*.RX!8J"0,^@-4?
MV)_@KJ?[.G[+'@[P1K,]G=:IX>LVM[B6U9FA=C*[_*6`)&&`Y`KA3J_6[6]S
ME_&Y5O=N>JT445W$GP]X:_X++V=O\9O%.D>+?`][H7@KPWXAF\.3>*+:Y-W#
M9W"RR)$;B,(#&D@C;Y@3@@CG!->M_MA?MX6_[,VC_#C4=*TFT\5Z?\0-:ATR
M*XAOPD4<4@4B9&56#Y#9'0>]<S^Q[^P7J/PC\6?'3_A.%\.Z_P"'/BGKAU"W
MLD#3J8&EN7*3*Z``XF3@%N5)STKR/XN_\$A_&$/B_P`-Z9\/_&-H/AAI'B*W
M\0QZ#KDLKRZ+*C'S$M9`K%HV4GY&(P>22?FKYSGS&-!NUVWY)KWK?--?<;)P
MN?H11117T2,3Y^_:#_;ZTCX0_&;1OACX<T#4/'/Q*UY0]OH]G.EM%;(49_,N
M)W^6-=B,W`8[5S@9&=4^,OCY';I<?\('\-)"V"UH/%5T)4![;S9[21],5Q7[
M0?[!FL:S^U%IOQM^&WB.PT+Q[9VPL[RTU:U:XTS58O*,6'V$/&WED+N7/"+P
M""3W%MXD^/<MJ()/!_PM@N0,&[_X26\>'/\`>\K[&&Q[;_QKR8RK>TFJUTKZ
M66EON>O<U5K*Q[#I5Q<7.GP/=PQ6]TT:F:..0R)&Y'S*K$*6`.0#@9]!TJQ5
M30FNVTBV-^MNE\8D^T"`L8A)CYMA."5SG&><5;KUDS(****8!1110!G^*/"N
MG>-=$N=,U:RM-2TZ\C,4]M<Q++#,IZJRL""/8BOAW]IC_@@S\-_B?=7&I>!=
M2O\`P%J,Y+FV1?MFFENO$;$/'D_W7VCLO:OO*BN+%Y?0Q,>6M%/\_O*C-Q=T
M?BGXS_X(D_M!_"756N?#":3X@\HEHKC1]7%K,/0XF\H@_0FLR/\`9^_;7\/+
M]EAA^,<:1\!8-<G=!]"LQ'Y5^W]%>.^%Z"_AU)17DS55WV/P\G_8!_:[^.&V
M#6])\:7MNY^9M>\0H(Q]5EF+?DIKUOX(_P#!O7XLU:[AN?B#XRTK1;4G<]KH
M\;7ERPZ[?,<(B'KR`]?K113I<+X2+YJC<_5Z![>730\5_9>_X)_?"_\`9$LE
M/A'P_&-5*;)=7O6%QJ$PQS^\(^0'NJ!5]J]JHHKWZ-"G2BH4U9>1BVV[L***
M*U$%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
'!1110!__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
